Clopidogrel bisulfate (Plavix®), an antiplatelet agent for treating thrombotic conditions is marketed by Bristol-Myers Squibb and Sanofi-Aventis. Now, generic clopidogrel is marketed by Apotex, before a court order halted further production until resolution of an existing patent infringement case brought by Bristol-Myers Squibb and Ssanofi-Aventis. The analyst opinion article reviews the legal wranglings over Plavix® and questions whether the generic version of Plavix launched by Apotex would remain in market for full 5 years before the Plavix patent is due to expire in the US.